Evidence map›Paper›PMID 36406127›Full record

ArticleFrontiers in genetics2022

A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study.

Huihuang Li, Jiao Hu, Xiongbing Zu, Minfeng Chen, Jinbo Chen, Yihua Zou, Ruoping Deng, Gang Qin, Wenze Li, Jiansheng Tang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Huihuang LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jiao HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Xiongbing ZuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Minfeng ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yihua ZouDepartment of Urology, The First People's Hospital of Chenzhou, Chenzhou, China.
Ruoping DengDepartment of Urology, The Central Hospital of Yongzhou, Yongzhou, China.
Gang QinDepartment of Urology, The Central Hospital of Yongzhou, Yongzhou, China.
Wenze LiDepartment of Urology, The First People's Hospital of Xiangtan City, Xiangtan, China.
Jiansheng TangDepartment of Urology, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Dingshan DengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Jinhui LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Chunliang ChengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Yu CuiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Zhenyu OuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CNChenzhou First People's Hospital · CNXiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bladder carcinomaneoadjuvant chemotherapypathological responsepersonalized therapyrisk score

Identifiers

PMID36406127
PMCPMC9667090
OpenAlexW4308123923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.